Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Funding Boost for LambdaVision’s Artificial Retina
LambdaVision, a pioneering company dedicated to developing a protein-based artificial retina aimed at restoring sight lost to retinal degenerative diseases, announced the successful first closing of its seed round to advance its artificial retina development. The funding injection will fuel…
Quantel Medical Launches POCKET III
Quantel Medical, a division of Lumibird Medical, has unveiled its latest innovation with the launch of the POCKET III handheld pachymeter. This compact device, according to Quantel, sets a new standard as the lightest connected handheld pachymeter on the market,…
Zeiss Introduces Upgraded Cirrus 6000 OCT
Zeiss Medical Technology has introduced a series of enhancements to the Cirrus 6000, promising a more streamlined and data-centric workflow for ophthalmologists. This update boasts the largest OCT reference database in the US market and fortified cybersecurity features. With recent…
AAO’s Tool for Enhanced IOL Cataract Surgery
The U.S. Food and Drug Administration (FDA) has qualified the Assessment of IntraOcular Lens Implant Symptoms (AIOLIS), developed by the American Academy of Ophthalmology (AAO), as a Medical Device Development Tool (MDDT). This designation empowers medical device sponsors to employ…
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
Merck & Co Nears $1.3 Billion Acquisition of Eyebiotech
Merck & Co, a global pharmaceutical giant, has finalized a monumental deal worth $3 billion to acquire EyeBio, a leading developer of eye-focused drugs. The agreement includes an upfront payment of $1.3 billion in cash, along with an additional $1.7 billion…
USC Roski Eye Institute Investigates Promising Drugs for TED
The USC Roski Eye Institute is making significant strides in the realm of Thyroid Eye Disease (TED) treatment through pioneering clinical trials exploring new medications. TED, a condition characterized by bulging eyes and potential vision impairment, has traditionally necessitated multiple…
Outlook Therapeutics Seeks UK Approval for Wet AMD Drug
Outlook Therapeutics announced the submission of its Marketing Authorisation Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in a press release. The MAA is for bevacizumab gamma (ONS-5010/LYTENAVA), its investigational formulation of bevacizumab for the…
Rezolute’s Phase 2 Success with Oral DME Drug
Rezolute announced promising topline results from its Phase 2 clinical study of RZ402. This study targeted patients with diabetic macular edema (DME) who were either naïve to or had limited exposure to anti-vascular endothelial growth factor (anti-VEGF) injections. Monumental Results…
KDB GLIDE FDA 510(k) Clearance for Expanded Glaucoma Use
New World Medical announced a significant milestone with the receipt of 510(k) indication expansion from the U.S. Food and Drug Administration (FDA) for KDB (Kahook Dual Blade) GLIDE. This clearance allows for the reduction of intraocular pressure (IOP) in adult…